Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years~2. Currently receiving cART and having received cART for a minimum of 1 year~3. HIV-1 plasma RNA \<50 copies/mL for at least 1 year (excluding viral load blips)~4. CD4 T cell count ≥500 cells/mm3~Exclusion Criteria:~1. CD4 T cell count nadir \<200 cells/mm3~2. Previous treatment with an HDACi (Histone deacetylase inhibitor) within the previous 6 months~3. Any evidence of an active AIDS-defining opportunistic infection, active HBV or HCV co-infection, significant cardiac disease, malignancy, transplantation, insulin dependent diabetes mellitus or other protocol defined excluded medical condition~4. Use of any protocol defined contraindicated medication or vaccination~5. Unacceptable values of the hematologic and clinical chemistry parameters as defined in the protocol.~6. Males or females who are unwilling or unable to use protocol defined methods of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A (Type: OTHER): Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of \~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir.
- Part B (Type: OTHER): Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of \~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33).

Based on this trial design, predict the completion outcome and termination type (if applicable).